Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200496 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL922165 | 0.86 | TSHR (0.53) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL7864367 | 0.85 | LMNA (0.43) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL14010927 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL1457077 | 0.82 | TSHR (0.61) | ALDH1A1KDM4EHSD17B10LMNATSHR | |
| SCHEMBL5822166 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL27958108 | 0.81 | HPGD (0.40) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL14033994 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL28373751 | 0.80 | MAPT (0.54) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL70220 | 0.80 | MAPT (0.65) | ALDH1A1KDM4EHSD17B10HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398813-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-12-05 | — | — | US | disclosed |
| CN-117820337-A | Preparation method of 12H-benzo [4,5] thiazolo [2,3-b ] quinazoline 12-ketone compound | 赣南师范大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-01-04 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023113114-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | 광주과학기술원 | 2023-06-22 | — | — | WO | disclosed |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220204484-A1 | CHEMICAL INHIBITION OF THE E3 LIGASE SUBUNIT FBXO7 CONFERS NEUROPROTECTION AND ANTI-INFLAMMATORY ACTIVITY BY STABILIZING MITOCHONDRIA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-4888426-A | CHEMICAL INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-12-19 | — | — | US | disclosed |
| US-4839374-A | TREATING ALLERGIES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1989-06-13 | — | — | US | disclosed |
| US-4695569-A | ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-09-22 | — | — | US | disclosed |
| US-4695575-A | ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-09-22 | — | — | US | disclosed |
| EP-0151826-A1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-08-21 | — | — | EP | disclosed |
| EP-0144101-A2 | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-12 | — | — | EP | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| US-4335127-A | POTENT SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
| EP-0013612-A2 | (Piperidinylalkyl)quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398813-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | KCNK5, KCNAB1, KCNQ5 | ALDH1A1 1211/4885KDM4E 1908/4885HSD17B10 3157/4885 |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | ALDH1A1 2421/4885KDM4E 669/4885HSD17B10 382/4885 |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | ALDH1A1 2547/4885KDM4E 657/4885HSD17B10 407/4885 |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | ALDH1A1 2421/4885KDM4E 669/4885HSD17B10 382/4885 |
| US-20220204484-A1 | CHEMICAL INHIBITION OF THE E3 LIGASE SUBUNIT FBXO7 CONFERS NEUROPROTECTION AND ANTI-INFLAMMATORY ACTIVITY BY STABILIZING MITOCHONDRIA | FBXL19, MAVS, XIAP | ALDH1A1 1963/4885KDM4E 744/4885HSD17B10 981/4885 |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | ALDH1A1 2421/4885KDM4E 669/4885HSD17B10 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.